Quantcast

Latest CancerVax Stories

2009-07-29 15:00:00

BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole book running manager, with RBC Capital Markets as co-manager in this offering. The offering is being made pursuant to a shelf registration...

2009-07-27 06:00:00

BETHESDA, Md., July 27 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, August 6, 2009, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its financial results for the second quarter of 2009. Micromet anticipates releasing its financial results at 7:00...

2009-06-29 10:00:00

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it was added to the Russell 3000 Index as part of the annual reconstitution of the Russell indexes, which occurred on June 26, 2009. "Investors recognize the Russell 3000 as an established benchmark for tracking investment performance, market movements and...

2009-06-18 06:00:00

BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulocyte macrophage colony-stimulating factor (GM-CSF) human antibody MT203 by its collaboration partner Nycomed. The double-blind, randomized, placebo controlled study will investigate the safety and...

2009-06-08 06:00:00

Data Presented at Meeting of European Hematology Association Confirms High Response Rate and Durability of Remissions BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, last week presented an update from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) for non-Hodgkin's lymphoma (NHL) at the 14th Congress of the...

2009-06-08 06:00:00

German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented phase 2 clinical data of the BiTE(R)...

2009-06-02 06:00:00

BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast on June 8, 2009 to discuss the blinatumomab data presented on June 5th and 6th at the 14th Congress of the European Hematology Association. The webcast will be available on the company's website at www.micromet-inc.com. Forum:...

2009-06-01 06:00:00

Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in patients with metastatic...

2009-05-20 06:00:00

Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA) Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting BETHESDA, Md., May 20 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced an oral(1) and a poster...

2009-05-13 09:54:00

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- AlphaVax announced today the presentation of promising results from a collaboration with researchers at the Memorial Sloan-Kettering Cancer Center (MSKCC). Francesca Avogadri, Ph.D., a Research Fellow in the Department of Medicine at MSKCC presented data at the American Association of Immunologists Annual Meeting in Seattle, Washington. Results from pre-clinical studies conducted at MSKCC demonstrate the ability of AlphaVax's virus-like...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.